Rationale: S100A12 is a small calcium binding protein that is a ligand of RAGE (receptor for advanced glycation end products). RAGE has been extensively implicated in inflammatory states such as atherosclerosis, but the role of S100A12 as its ligand is less clear. Objective: To test the role of S100A12 in vascular inflammation, we generated and analyzed mice expressing human S100A12 in vascular smooth muscle under control of the smooth muscle 22␣ promoter because S100A12 is not present in mice. Methods and Results: Transgenic mice displayed pathological vascular remodeling with aberrant thickening of the aortic media, disarray of elastic fibers, and increased collagen deposition, together with increased latent matrix metalloproteinase-2 protein and reduction in smooth muscle stress fibers leading to a progressive dilatation of the aorta. In primary aortic smooth muscle cell cultures, we found that S100A12 mediates increased interleukin-6 production, activation of transforming growth factor ␤ pathways and increased metabolic activity with enhanced oxidative stress. To correlate our findings to human aortic aneurysmal disease, we examined S100A12 expression in aortic tissue from patients with thoracic aortic aneurysm and found increased S100A12 expression in vascular smooth muscle cells. Conclusions: S100A12 expression is sufficient to activate pathogenic pathways through the modulation of oxidative stress, inflammation and vascular remodeling in vivo. (Circ Res. 2010;106:145-154.) 
M embers of the S100/calgranulin family such as S100A8 (myeloid related protein-8; calgranulin A), S100A9 (myeloid related protein-14; calgranulin B), and S100A12 (EN-RAGE; calgranulin C), are members of the calcium binding proteins implicated in the regulation of a variety of intracellular and extra cellular activities. 1 They are endogenously expressed in cells intimately linked to vascular disease such as granulocytes and myeloid cells. Calgranulins are associated with disease activity in chronic inflammatory diseases, such as rheumatoid arthritis, 2,3 inflammatory bowel disease, 4 asthma, 5 and Kawasaki vasculitis. 6 In a number of clinical settings, serum concentrations correlate with disease activity and, therefore, may serve as biomarkers of cell stress. 6, 7, 1 Calgranulins promote inflammation and vascular perturbation by activating RAGE (receptor for advanced glycation end products) 8 and toll-like receptor-4 9 ; both receptors are strongly linked to vascular dysfunction and atherosclerosis. 10, 11 The importance of RAGE as a mediator of vascular stress and inflammation in atherosclerosis was recently shown in apolipoprotein E-null mice that also lacked RAGE.
In the absence of RAGE, apolipoprotein E-null mice developed significantly less atherosclerosis in euglycemic and hyperglycemic conditions. 12, 13 Less is known about the RAGE ligands, the S100/calgranulins. S100/calgranulins are not detectable in normal vascular smooth muscle cells (VSMCs) but are induced in VSMCs after endothelial cell wire injury, 14 and in neovascular SMCs in the atherosclerotic arterial wall. 15 Burke et al found strong expression of S100A12 in human coronary artery SMCs associated with plaque rupture and sudden cardiac death, 16 suggesting that S100A12 is either a marker or mediator of VSMC dysfunction.
To study this issue, we exploited the fact that S100A12 is not present in mice 17 and generated transgenic (TG) mice expressing human S100A12 in VSMCs driven by the smooth muscle (SM)22␣ promoter. We found aneurysmal dilatation of the aorta with disarray of elastic fibers, increased fibrosis, increased matrix metalloproteinase (MMP)-2 protein, and reduction in VSMC contractile elements. Furthermore, cultured aortic VSMCs from TG mice had increased production of cytokines and elevated measures of oxidative stress. We next examined human aortic tissue obtained from patients with thoracic aortic aneurysms (TAAs) and found strong expression of S100A12 in the VSMCs near the site of cystic media necrosis. Together these data demonstrate that expression of S100A12 in VSMCs is sufficient to modulate aortic wall remodeling and suggest that overexpression of S100A12 in human aortic aneurysms is pathogenic.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and contains details on generation of TG (TG) mice expressing human S100A12 in VSMCs driven by the SM22-␣. Hemizygous TG mice were mated with C57BL6/J (The Jackson Laboratory). TG and wild-type (WT) littermates not expressing the transgene were used for all experiments. All procedures were carried out with the approval of the Institutional Animal Care and Use Committee of The University of Chicago. Human vascular tissue was obtained with informed consent and approved by the University of Chicago Institutional Review Board.
Results

Generation of TG Mice Expressing Human S100A12 in Aortic Smooth Muscle
Human S100A12 was expressed in TG mice under control of the SM22␣ promoter ( Figure 1A ). Of the 9 S100A12 founder animals, 3 lines were propagated based on a variable copy number. TG mice developed normally and were fertile and healthy. There were no differences in body weight, plasma cholesterol and blood pressure between TG and WT littermate mice (Online Table I ). Mating of hemizygous TG mice with C57BL/6J WT mice produced Ϸ50% TG offspring with an equal gender distribution. TG and WT mice, age 12 to 15 months, had no differences in mortality (5% versus 7%, nϭ20 for each group; PϭNS).
Expression of S100A12 protein within the vasculature was examined by immunofluorescence microscopy in 10-week old mice ( Figure 1D ). S100A12 was detected in the VSMC-rich medial layer of the aorta from TG but not in WT mice. Furthermore, primary aortic VSMCs from TG mice, but not from WT littermates, expressed S100A12 when cultured for up to 8 passages ( Figure 1E ). Expression of S100A12 protein was detected in tissue extracts rich in vascular smooth muscle cells, including the aorta and lung ( Figure 1F and Online Table I ). No expression was detected in the esophagus, stomach, urinary bladder, kidney, liver, and brain (data not shown).
To compare S100A12 protein expression between TG mice and humans with aortic disease, we performed semiquantitative immunoblotting using 10 g of protein extract from the ascending aorta of patients undergoing aortic root repair for TAAs. S100A12 expression in TG animals was comparable to protein levels observed in patients with aneurysmal aortic disease ( Figure 1G ). VSMCs were cultured from those surgical samples and increased expression of S100A12 was observed in TAA-SMCs but not in control SMCs ( Figure 1H ). This increase is not explained by contaminating leukocytes in the primary VSMC culture, because immunoblotting and quantitative RT-PCR for CD68 and CD 45 was negative (data not shown). Stimulation with lipopolysaccharide (LPS) (1 g/mL) revealed a strong upregulation of S100A12 in both, control and TAA-SMCs and is comparable to the expression level achieved in cultured SMCs from TG aorta ( Figure 1H ).
S100A12 TG Mice Have Pathological Aortic Remodeling
The aorta was examined in 10-and 16-week-old TG and WT littermate mice. TG mice displayed disrupted aortic wall architecture which was seen at age 10 weeks and was more pronounced at 16 weeks of age ( Figure 2 ). Histological grading of medial elastin degradation revealed a significant increase in elastin fiber disruption in TG mice (grade 2 for 10-week-old TG mice and grade 2 to 3 for 16-week-old TG mice compared to no elastic fiber disruption in WT mice; Figure 2Q ). Furthermore, we observed aberrant aortic wall thickening in TG mice. Quantification of the aortic wall thickness from histology sections of the aortic arch revealed significant increase in wall thickness at 10 and 16 weeks of age ( Figure 2R ). In parallel, the TG mice showed loss of VSMCs and overt fibrosis within the medial layer of the aorta as demonstrated by Masson trichrome staining ( Figure 2J and 2L). Quantitative analysis of the aortic arch revealed increased fibrosis in the medial layer in TG mice at 10 weeks (12Ϯ4% versus 2Ϯ0.4%) and at 16 weeks (22Ϯ3% versus 3Ϯ0.3%) compared to WT littermates ( Figure 2S ). This phenotype was also present in other TG lines (Online Figure I) . S100A12 protein is a monocytes chemoattractant, resulting in neutrophil and monocyte recruitment in vivo. 5, 8, 18 We therefore examined aortic tissue to evaluate if infiltration of inflammatory cells precedes the pathological remodeling observed in 10-week-old mice. At 4 and 6 weeks of age, TG aorta showed normal architecture with normal wall thickness, absent fibrosis, and no inflammatory cells within the aortic wall, either in the vasa vasorum or intima or media (data not shown). Because detection of infiltrating leukocytes by microscopy has limited sensitivity, we assayed aortic tissue for myeloperoxidase (MPO), a heme protein derived from leukocytes. 19 Expression of S100A12 in smooth muscle resulted in a significant increase in MPO activity in TG aorta. This was observed at all ages studied, but most profoundly in TG mice with established aortic remodeling at age 10 and 16 weeks ( Figure 2T ). Enhanced MPO activity is linked to generation of oxidative stress, and therefore may initiate or exacerbate dysfunction of VSMCs in the TG mice. In aortic tissue of 8-week-old mice, we found a reduction of vinculin, smooth muscle myosin heavy chain, and smooth muscle ␣-actin. We noted an increase of VCAM-1 in the aortic tissue of TG mice ( Figure 3A ). Furthermore, we found increased MMP-2 protein in the aortic tissue of TG mice compared to WT mice using gelatin zymography (6.2 fold; PϽ0.001; Figure 3B ). To elucidate whether this increase depends on infiltrating leukocytes, we assayed cultured aortic SMCs from TG aorta and WT aorta. TG-SMCs showed a significant upregulation of MMP-2 protein ( Figure 3C ). This increase was largely attributable to the latent form of MMP-2, because activated MMP-2 (marked by arrowhead in Figure 3 ) was only minimally increased in TG-SMCs, demonstrating that S100A12 is directly linked to increased MMP-2 levels in VSMCs. TG mice developed aortic aneurysms. We examined the aortic root and the midaortic arch using serial in vivo echocardiography at age 10 weeks, 16 weeks and 22 weeks (nϭ4 for each group; Figure 4 ). At 10 weeks of age, no difference between TG and WT mice was observed in the aortic root size ( Figure 4 ) and in the size of the aortic arch (data not shown). At age 16 and 22 weeks, the aortic root and arch were consistently dilated in the TG mice compared to WT littermates. In TG male mice, the aortic root increased significantly at age 16 weeks by Ϸ23% (1.72Ϯ0.19 mm; Pϭ0.01) and only Ϸ5% in WT mice (1.45Ϯ0.17 mm; PϭNS), and remained dilated without further changes at age 22 weeks (1.75Ϯ0.15 and 1.46Ϯ0.11 mm). In TG female mice, the aortic root increased significantly at age 16 weeks by Ϸ20% (1.59Ϯ0.17 mm; Pϭ0.01) and only Ϸ5% in WT mice (1.33Ϯ0.15 mm; PϭNS) and remained dilated without further changes at age 22 weeks (1.61Ϯ0.12 and 1.32Ϯ0.17 mm). Similarly, measurements for the aortic arch dimensions were equal at the 10-week baseline measurement, and TG mice had an Ϸ20% increase at age 16 weeks without further progression at 22 weeks (both sexes; data not shown). We did not observe spontaneous rupture of the aorta, and there was no difference in mortality between TG and WT littermates observed in mice aged up to 15 months.
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S100A12 Augments Cytokine Production in Vascular Smooth Muscle Cells
Previously it was shown that S100A12 induces upregulation of proinflammatory cytokines, most notably induction of 
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TG-SMC WT-SMC Figure 1 . Generation of S100A12 TG mice. A, Human cDNA S100A12 was expressed under control of the smooth muscle promoter SM22␣. B, PCR showing TG ϩ mice. C, Southern blotting revealed S100A12 incorporation. D, Immunofluorescence microscopy of aortic frozen sections from WT mice (top) and TG mice (bottom) were stained with ␣-S100A12 IgG (red), ␣-smooth muscle actin IgG (SMA) (green) and DAPI (blue). E, Immunofluorescence microscopy of cultured primary VSMCs isolated from WT mice (left) and TG mice (right) were stained with ␣-S100A12 IgG (red) and DAPI (blue). Scale barϭ10 m. Immunoblotting with ␣-S100A12 IgG of 10 g whole cell lysates from cultured VSMCs shows no S100A12 expression in WT-VSMCs (lanes 1 to 3) and strong S100A12 expression in TG-VSMCs at passage 3 to 8 (lanes 4 to 6). F, Immunoblotting with ␣-S100A12 IgG of lung and aortic tissue extracts reveals S100A12 protein expression in TG but in WT mice. G, Immunoblotting with ␣-S100A12 IgG and ␤- interleukin (IL)-6 in RAGE-bearing human monocytes 2 and in human cord blood-derived mast cells lacking RAGE expression. 5 We therefore tested the hypothesis that S100A12 augments IL-6 production in cultured primary aortic VSMCs harvested from TG mice and WT littermate controls. IL-6 was increased in the cell culture supernatant from S100A12 expressing VSMCs compared to WT-VSMCs (417Ϯ35 versus 160Ϯ20 ng/mL; Pϭ0.001; Figure 5A ). This difference did not derive from variable leukocyte contamination in the cultured primary aortic VSMCs as assessed by immunoblot using anti-murine CD45 IgG and by RT-PCR using specific primers (data not shown). In VSMCs, IL-6 is induced on stimulation with LPS. 20, 21 At 1 g/mL, a dose not associated with cytotoxic effects (data not shown), there was a significant increase in IL-6 production in both TG-VSMCs and WT-VSMCs (2130Ϯ160 and 415Ϯ54 ng/mL, respectively; Pϭ0.001). However, the increase was 5 fold higher in the S100A12 expressing VSMCs (PϽ0.01; Figure 5A ). Pretreatment of the VSMCs with 5 and 10 g/mL of soluble RAGE attenuated the LPS induced IL-6 secretion by 40% in the TG-VSMCs (1278Ϯ65 and 1345Ϯ69 ng/mL, respectively; PϽ0.05) but not in WT-VSMCs (390Ϯ61 and 410Ϯ56 ng/mL, respectively; PϭNS); soluble RAGE had no effect on baseline IL-6 secretion in TG-or WT-VSMCs. We examined whether S100A12 was released into the cell supernatant where it could activate VSMC surface RAGE. S100A12 was not detected in either cell supernatant from TG-VSMCs or WT-VSMCs under basal conditions, but was detected in the supernatant of TG-VSMCs on stimulation with low dose LPS (1 g/mL; Figure 5B ), suggesting that S100A12 may amplify LPS induced IL-6 production in a RAGE-dependent manner. IL-6 was measured in the supernatant of freshly harvested aortic rings (nϭ4 mice per group). At baseline, there was no difference in the IL-6 production, but in response to stimulation with 1 g/mL LPS, the aortic ring tissue from TG mice produced 2.2 fold more IL-6 than the aortic tissue from WT mice (980Ϯ175 and 450Ϯ51 ng/mL, respectively; Pϭ0.03; Figure 5C ). We next examined serum IL-6 levels in TG and WT littermate mice housed in a barrier facility ( Figure 5D ). There was no difference in serum IL-6 at 4 weeks (41Ϯ5 and 50Ϯ8 ng/mL; PϭNS) and at 8 weeks (45Ϯ7 and 43Ϯ8 ng/mL; PϭNS). As the mice aged, we found increased serum IL-6 in TG mice at 12 weeks (95Ϯ18 and 55Ϯ10 ng/mL; Pϭ0.04) and at 16 weeks (135Ϯ15 and 55Ϯ11 ng/mL; Pϭ0.01, nϭ6 in each group and time point).
The increased collagen deposition in the aortic medial layer and the histological changes in S100A12 TG mice are similar to the aortic remodeling observed in mice that model Marfan syndrome. 22, 23 Fibrillin-1 regulates transforming growth factor (TGF)-␤ sequestration and in the presence of fibrillin-1 mutations, there is an increase in TGF-␤ availability and increased Smad2 phosphorylation and nuclear localization. 23 Similar to Marfan syndrome, aortic VSMCs from S100A12 TG mice displayed increased phosphorylation and nuclear translocation of Smad2 ( Figure 5E ). Furthermore, nuclear translocation of pSmad2 depends on the availability of TGF-␤, because treatment of TG-VSMCs with neutralizing TGF-␤ antibody prevented nuclear translocation of pSMAD2 ( Figure 5E ).
S100A12 Expression Increases Oxidative Stress and Metabolic Activity in Vascular Smooth Muscle Cells
We investigated the effect of S100A12 on VSMC proliferation because some members of the S100 protein family have been implicated in VSMC migration, proliferation, and cy- toskeletal metabolism. 14, 24 Specifically, TG S100A4 expression leads to medial and intimal changes in the pulmonary circulation similar to pulmonary artery hypertension. 25 Surprisingly, cell proliferation of cultured primary aortic TG-VSMCs was reduced (7Ϯ2% versus 28Ϯ3% 5-bromodeoxyuridine [BrdUrd]-positive nuclei, respectively; Pϭ0.03; Figure 6A ), and this difference was observed in cells cultured from 1 to 4 days. We then examined conversion of MTS into a formazan product as a reflection of metabolism. 26 We found that TG-VSMCs bioreduced MTS into formazan 1.9-to 2.7-fold more than WT-VSMCs ( Figure 6B ). Reduced proliferation, as assessed by BrdUrd, compiled with increased MTS conversion strongly supports increased metabolic activity as a result of S100A12 expression. Furthermore, transient transfection of rat A7r5 vascular smooth muscle cells with S100A12 revealed a 2.7 fold increased rate of MTS conversion (Online Figure II) . To explain this metabolic defect, we investigated whether the increased metabolic activity observed in the TG-VSMCs could be explained by altered mitochondrial function using flow cytometry with the fluorescent probes MitoTracker-Green and Mito-Sox. TG-VSMCs had significantly more MitoTrackerGreen fluorescent signal than WT-VSMCs (mean fluorescence 2455 versus 1140; Pϭ0.01; Figure 6C ), suggesting either increased mitochondria number or increased mitochondrial volume. Indeed, staining of VSMCs with MitoSox, an indicator for mitochondrial reactive oxygen species (ROS) production, showed significantly more fluorescent signal (101 versus 37; PϽ0.05, nϭ3; Figure 6D ), suggesting that S100A12 modulates mitochondrial function and superoxide formation. To confirm altered levels of oxidative stress, we stained VSMCs for 8-hydroxy-2deoxyguanosine, a marker for oxidative damage to the DNA and found increased nuclear staining in TG-VSMCs (82Ϯ6% and 3Ϯ3%, respectively; PϽ0.005; Figure 6E ). Because increased oxidative stress via the NADPH oxidase system in VSMCs depends on activation of cell surface RAGE, 27 we next examined whether the mitochondrial ROS production we observed in the S100A12 expressing VSMCs is also mediated through RAGE. Recombinant S100A12 (10 g/ mL) was added to the VSMC culture medium but did not increase the mean fluorescent signal for mitochondrial ROS production in WT-VSMCs (38Ϯ4 and 40Ϯ4) and TG-VSMCs (107Ϯ6 and 110Ϯ9) ( Figure 6F ). Furthermore, coculture of WT-and TG-VSMCs confirmed increased signal intensity for MitoSOX in S100A12 expressing VSMCs (Figure 6G ), suggesting a direct intracellular mechanism rather than a paracrine extracellular mechanism of S100A12 induced mitochondrial ROS production.
S100A12 Is Expressed in Vascular Smooth Muscle Cells in Human Thoracic Aneurysms
To evaluate weather increased S100A12 occurs in human aortic diseases, we studied a 34 year old male with familial thoracic aneurysm syndrome. The patient (II.1 in Figure 7A ) developed a thoracic aneurysm affecting the proximal aorta, just above the sinus of Valsalva at the age of 24, and, at age 34, he developed marked dilatation above the previous repair site, necessitating repair. His brother displayed a similar course with a first dissection at the age of 23 and a second repair at the age 33, and both were non-Marfanoid. The patient underwent clinical genetic evaluation for fibrillin-1, TGF-␤ receptor-1, TGF-␤ receptor-2, ACT2, and MYH11. A novel mutation was identified in MYH 11 c3757-3759delAAG, leading to the deletion of amino acid 1253, a lysine. The histopathology of the resected proximal aorta showed disruption of the tunica media with accumulation of myxoid material, degeneration and loss of VSMCs, as well as disruption of the elastic fibers, consistent with cystic medial necrosis (Figure 7) . Strong expression of S100A12 protein was seen in the medial layer, particularly in areas of degeneration and dissection. S100A12 was not detected in control aortic tissue. The S100A12 staining colocalized with smooth muscle actin positive staining ( Figure 7E ).
Discussion
S100A12 is constitutively expressed in neutrophilic granulocytes where it accounts for up to 5% of the cytoplasmic protein.
As it relates to chronic vascular pertubation, S100A8/9 are present in foam cells and endothelial cells in the atherosclerotic aortic wall 15 and elevated plasma levels of the S100A8/9 heterodimer are associated with increased risk of cardiovascular events. 28 Furthermore, transcriptional profiling of platelets identified S100A8/9 as a novel regulator of atherothrombosis 29 and S100A12 was identified in SMCs in ruptured coronary artery plaques in patients with sudden cardiac death. 16 Together, these data suggest a possible role of S100A12 in mediating VSMC dysfunction. Beyond serving as a marker for atherothrombotic risk, it is still unclear whether S100A12 indeed regulates the development of vascular disease. To determine whether S100A12 expression is sufficient to mediate vascular disease, we expressed human S100A12 in murine vascular smooth muscle cells. S100A12 expression was sufficient to change the phenotype of VSMCs with increased IL-6 production, enhanced TGF-␤ signaling pathways, increased oxidative stress, and increased MMP2 protein. Whereas our in vitro studies using cultured VSMCs from WT and TG aorta demonstrated a direct effect of S100A12 on VSMCs, the biology leading to aortic remodeling appears likely to be more complex in vivo. We found increased MPO activity in aortic tissue as evidence for infiltrating leukocytes, although inflammatory cells were not yet seen on histology. We speculate that enhanced MPO activity triggers oxidative stress, thereby providing at least in part an environment capable of augmenting VSMC dysfunction, leading to remodeling of the aortic wall with aneurysm formation. In vivo, we found markedly reduced expression of contractile SMC fibers and increased collagen accumulation, together with increased MMP-2 levels and increased elastin fiber breakdown. It is interesting, that S100A12 augments the levels of latent MMP-2 but had only minimal effect on the active form of MMP-2 when assessed by standard gelatin zymography. Accumulation of extracellular matrix proteins despite increased MMP proteins may seem at first contradictive, but recent studies using human thoracic aneurysmal tissue have found the exact same findings and support the hypothesis that dysregulated synthesis of extracellular matrix could act indirectly to either induce or to further increase MMP synthesis and increase ECM degradation. 30 Figure 6 . Effect of S100A12 on metabolic activity in cultured VSMCs. A, Incubation of cultured VSMCs with BrdUrd showed reduced proliferation. B, VSMCs were treated with MTS and TG-VSMCs were shown to have increased metabolic activity. C and D, Flow cytometry of cultured VSMCs from WT and TG mice that stained with MitoTrackerGreen (C) and MitoSOX (D), consistent with increased mitochondrial content in TG-VSMCs. E, Immunofluorescence microscopy of cultured WT-VSMCs (left) and TG-VSMCs (right) with ␣-8-oxo-dG IgG (red color) and DAPI (blue color) showed an increase in ␣-8oxo-dG staining. *PϽ0.005. F, WT-VSMCs and TG-VSMCs were stimulated with BSA or recombinant S100A12 and stained with MitoSOX and analyzed by fluorescenceactivated cell sorting for mean fluorescence intensity. G, WT-VSMCs and TG-VSMCs were cocultured for 3 days before staining with MitoSOX dye (green) and ␣-S100A12-IgG (red). Fluorescence intensity was measured in TG-VSMCs and WT-VSMCs on 5 power fields. *PϽ0.005.
We found S100A12 increases LPS induced IL-6 production in VSMCs. Some S100A12 may be released and mediate effects through cell surface receptors. However, the observation that soluble RAGE could only partially block LPS induced IL-6 production argues for the importance of intracellular S100A12. We speculate that S100A12 may serve as an amplifier of LPS signaling. To explain the pathology in S100A12 TG mice, it is possible that normal amounts of LPS present in a pathogen free mouse barrier facility may propagate enough IL-6 in the VSMCs of S100A12 TG mice to sustain vascular inflammation and remodeling. TG mice have normal vascular morphology by histology in the first weeks of life but develop morphological remodeling by the age of 8 to 10 weeks, followed by functional impairment, leading to aneurysmal dilation. This time course suggests that environmental factors may trigger or augment SMC dysfunction in S100A12 TG mice, and exposure to pathogens may be among those triggers. Based on our in vitro results ( Figure 5 ), we hypothesize that a more proinflammatory environment would alter the severity of vascular remodeling and possibly lead to rupture of the aneurysmal remodeled aorta. However, under the conditions described here in a pathogen-free barrier facility, we did not observe impaired survival or rupture of the aortae. Therefore, S100A12 may accelerate vascular disease via increased IL-6 production under conditions asso-ciated with increased endotoxin levels. In humans, increased endotoxin levels have been found in periodontal disease, chronic inflammatory bowel diseases, and cigarette smoking, 32, 33 and this may all be sufficient to increase S100A12 levels and amplify IL-6 production. Furthermore, we demonstrated increased metabolic activity and mitochondrial ROS production in cultured TG-VSMCs. S100 proteins have been previously shown to increase cytosolic H 2 O 2 production via the NADPH oxidase system in VSMCs. 27 Activation of RAGE by advanced glycation end products is associated with mitochondrial superoxide generation in rat mesangial cells when cultured in high glucose medium. 34 Together, these data suggest a role for AGE/ RAGE mediated mitochondrial dysfunction. Our studies here demonstrate that intracellular expression of S100A12 can serve as a potent inducer of mitochondrial ROS. Of interest, S100A12 and its homolog S100A8/9 are associated with strong antimicrobial activity and have cytostatic effects when added to mammalian cell lines. 35, 36 In agreement with those findings, we found reduced proliferation of VSMCs from S100A12 TG mice using BrdUrd incorporation as the measurement for cell proliferation. Of interest, other cell proliferation assays using bioreduction of MTS to formazan showed increased activity reflecting an increase in metabolic activity. Figure 7 . S100A12 is expressed in VSMCs in human aortic tissue with cystic media necrosis. A, Pedigree of a family with familial thoracic aneurysms with the MYH11 mutation. Affected family members with aortic dissection and aortic valve replacement are indicated by f. B and C, Three-dimensional reconstruction of the computed tomography scans of the proximal aorta shows a 5.2-cm aneurysm distal the area of prior aortic repair. D, Resected TAA aorta and control aortic tissue were stained using Verhoeff-van Giessen (VVG), ␣-smooth muscle actin (SMA), and ␣-S100A12 antibodies. The tunica interna, media (MEDIA), and adventitia (AD) are shown. E, Colocalization of SMA and S100A12 is shown by immunofluorescence microscopy.
Lastly, we identified strong expression of S100A12 in aortic SMCs with a novel MYH11 mutation. It was recently discovered that mutations in VSMC-specific ␤-myosin (MYH11) and ␣-actin (ACTA2) can also cause TAAs, focusing attention on the importance of the maintenance of SMC contractile function in preserving aortic structure and preventing TAAs. 37 The mechanisms leading to the expression of S100A12 in VSMCs in aneurysmal aortic vasculature are not well understood, but our data show that at least 1 mechanism leading to S100A12 expression in VSMCs can be mediated by LPS stimulation. S100A4, another member of the S100 family is endogenously expressed in VSMCs and promotes VSMC dedifferentiation. 24, 25 Furthermore, S100A4 levels are increased in TGF-receptor 2 mutant smooth muscle cells isolated from TAA patients (D. Milewicz, personal communication, 2008 ), suggesting a potential role of S100 proteins in mediating VSMC dysfunction and vascular disease. In summary, our data demonstrate that targeted expression of human S100A12 in murine VSMCs is sufficient to modulate VSMC function and promote vascular remodeling and identify S100A12 expression as a potential therapeutic target. 
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